KarXT (Karuna Therapeutics) met its primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia, the company has announced. KarXT is an oral coformulation of ...

Add Yahoo as a preferred source to see more of our stories on Google. Katie Melua recently opened up about suffering an acute psychotic breakdown in her 20s. (Getty Images) Being there for a loved one ...

The investigational combination xanomeline-trospium (KarXT) was effective and well tolerated in individuals with schizophrenia who were experiencing acute psychosis, according to the randomized ...

The EMERGENT-3 trial, published in the Journal of the American Medical Association Psychiatry, represents a significant advancement in the treatment of schizophrenia, particularly for individuals ...